Сравнение
Afamelanotide vs. Octreotide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
75921-69-6
83150-76-9
Молекулярная масса
1646.87 g/mol
1019.24 g/mol
Период полувыведения
12 h
1.7 h
Последовательность
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Механизм действия
Afamelanotide
Afamelanotide is a synthetic analogue of α-melanocyte-stimulating hormone. It differs from native α-MSH by two substitutions — norleucine at position 4 and D-phenylalanine at position 7 — which make it metabolically more stable and more potent. As an agonist at the melanocortin-1 receptor (MC1R) on melanocytes, it activates adenylate cyclase, raises cAMP and increases tyrosinase activity via the transcription factor MITF. This shifts pigment synthesis toward eumelanin, which absorbs UV and visible light and has antioxidant properties — the presumed mechanism of photoprotection in EPP.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
5
из них на людях
4
4
Зафиксированные эффекты
4
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
4
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Afamelanotide and Octreotide?
- Afamelanotide is classified as "Исследования (прочее)", while Octreotide is classified as "Исследования (прочее)". Afamelanotide: Afamelanotide (brand name Scenesse) is a synthetic 13-amino-acid analogue of α-melanocyte-stimulating hormone (α-MSH) and a melanocortin-1 receptor agonist. Unlike most peptides covered here, it is a regularly approved medicine: EMA approval in 2014/2015, FDA approval in 2019, in each case as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It promotes eumelanin formation in the skin. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Afamelanotide or Octreotide?
- The highest available evidence level is "РКИ на людях" for Afamelanotide and "РКИ на людях" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Afamelanotide and Octreotide in Germany and the United States?
- Германия: Afamelanotide — Рецептурный, Octreotide — Рецептурный. США: Afamelanotide — Рецептурный, Octreotide — Рецептурный. These are factual summaries with source and review date on the individual pages.